Brentuximab vedotin is an antibody-drug conjugate approved to treat anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma. The drug was approved in August by FDA.
Antibody drug conjugate consists of an antibody linked to a payload drug. This kind of mechanism helps to deliver the drug to targeted cells like cancer cells.
